title: Prognostic factors and treatment outcome in 1,516 adult patients with de novo and secondary acute myeloid leukemia in 1999-2009 in 5 hematology intensive care centers in the Czech Republic.
abstract: Acute myeloid leukemia (AML) is a severe condition with a high mortality. When making decisions about the optimal tailor-made therapy, numerous prognostic factors are considered. The study represents a detailed analysis of the role of these factors and treatment outcomes based on a long-term follow-up of patients treated in 5 hematology intensive care centers in the Czech Republic.The studied group comprised 1,188 patients with de novo AML and 328 patients with secondary AML. The latter were significantly older, had more unfavorable cytogenetic changes and less frequently received curative therapy. Curatively treated patients achieved fewer complete remissions and relapsed more often than those with de novo AML. Patients with secondary AML had lower rates of allogeneic transplantation as part of consolidation therapy and a significantly shorter median overall survival. A lower proportion of the patients were alive at the time of analysis. However, the treatment outcome of de novo AML patients is not satisfactory, the only exception being those with acute promyelocytic leukemia. The analysis, which did not evaluate the intention-to-treat criteria and was without randomization, found allogeneic stem cell transplantation to be the most effective modality of consolidation therapy in both groups of patients. .
authors.affiliation: Department of Hemato-Oncology, University Hospital Olomouc, Czech Republic. tszotkowski@seznam.cz
authors.forename: T
authors.initials: T
authors.lastname: Szotkowski
authors.forename: J
authors.initials: J
authors.lastname: Muzik
authors.forename: J
authors.initials: J
authors.lastname: Voglova
authors.forename: V
authors.initials: V
authors.lastname: Koza
authors.forename: J
authors.initials: J
authors.lastname: Maaloufova
authors.forename: T
authors.initials: T
authors.lastname: Kozak
authors.forename: M
authors.initials: M
authors.lastname: Jarosova
authors.forename: K
authors.initials: K
authors.lastname: Michalova
authors.forename: P
authors.initials: P
authors.lastname: Zak
authors.forename: K
authors.initials: K
authors.lastname: Steinerova
authors.forename: J
authors.initials: J
authors.lastname: Vydra
authors.forename: M
authors.initials: M
authors.lastname: Lanska
authors.forename: B
authors.initials: B
authors.lastname: Katrincsakova
authors.forename: K
authors.initials: K
authors.lastname: Sicova
authors.forename: T
authors.initials: T
authors.lastname: Pavlik
authors.forename: L
authors.initials: L
authors.lastname: Dusek
authors.forename: K
authors.initials: K
authors.lastname: Indrak
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002869:Chromosome Aberrations; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000209:etiology / Q000235:genetics / Q000401:mortality* / Q000628:therapy; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000401:mortality* / Q000628:therapy; D011379:Prognosis; D013997:Time Factors; D016896:Treatment Outcome